Abstract：
Photobiomodulation (PBM) therapy uses light of different wavelengths to treat various retinal degeneration diseases, but the potential damage to the retina caused by long-term light irradiation is still unclear. This study were designed to detect the difference between long- and short-wavelength light (650-nm red light and 450-nm blue light, 2.55 mW/cm2, reference intensity in PBM)-induced injury. In addition, a comparative study was conducted to investigate the differences in retinal light damage induced by different irradiation protocols (short periods of repeated irradiation and a long period of constant irradiation). Furthermore, the protective role of PARP-1 inhibition on the molecular mechanism of blue light-induced injury was confirmed by a gene knockdown technique or a specific inhibitor through in vitro and in vivo experiments. The results showed that the susceptibility to retinal damage caused by irradiation with long- and short-wavelength light is different. Shorter wavelength lights, such as blue light, induce more severe retinal damage, while the retina exhibits better resistance to longer wavelength lights, such as red light. In addition, repeated irradiation for short periods induces less retinal damage than constant exposure over a long period. PARP-1 plays a critical role in the molecular mechanism of blue light-induced damage in photoreceptors and retina, and inhibiting PARP-1 can significantly protect the retina against blue light damage. This study lays an experimental foundation for assessing the safety of phototherapy products and for developing target drugs to protect the retina from light damage.
摘要：
光生物调节（PBM）疗法使用不同波长的光来治疗各种视网膜变性疾病，但长期光照对视网膜的潜在损害仍不清楚。这项研究旨在检测长波长和短波长光（650nm红光和450nm蓝光，2.55mW/cm2，以PBM为参考强度）引起的损伤。此外,进行了一项比较研究，以研究不同照射方案（短期重复照射和长期持续照射）引起的视网膜光损伤的差异。此外，PARP-1抑制对蓝光诱导损伤的分子机制的保护作用通过基因敲低技术或特异性抑制剂通过体外和体内实验得到证实.结果表明，长波长和短波长光照射对视网膜损伤的敏感性不同。较短波长的灯，如蓝光，引起更严重的视网膜损伤，虽然视网膜对更长波长的光表现出更好的抵抗力，比如红灯。此外,短时间重复照射比长时间持续照射引起的视网膜损伤更少。PARP-1在蓝光诱导光感受器和视网膜损伤的分子机制中起关键作用,抑制PARP-1可以显著保护视网膜免受蓝光损伤。本研究为评估光疗产品的安全性和开发保护视网膜免受光损伤的靶向药物奠定了实验基础。
